Imaging software developer Median Technologies has received a notice of allowance from the U.S. Patent and Trademark Office for its application covering a set of computing systems and methods to extract biomarkers from medical images automatically.
The imaging biomarkers will allow physicians to identify and classify pathologies for most cancers, as well as to determine which patients are more likely to respond to a specific therapy and to assess their response to therapy, Median said. The biomarkers will be computed from standard techniques such as CT and MRI. The notice of allowance is for U.S. patent No. 9,092,691 B1.
The firm said it plans to continue its research and development activities within the field of advanced imaging biomarkers.
